These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10669049)

  • 1. Inhibition of human chymase by suramin.
    Takao K; Takai S; Ishihara T; Mita S; Miyazaki M
    Jpn J Pharmacol; 1999 Dec; 81(4):404-7. PubMed ID: 10669049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of human mast cell chymase by secretory leukocyte proteinase inhibitor: enhancement of the interaction by heparin.
    Walter M; Plotnick M; Schechter NM
    Arch Biochem Biophys; 1996 Mar; 327(1):81-8. PubMed ID: 8615699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chymase bound to heparin is resistant to its natural inhibitors and capable of proteolyzing high density lipoproteins in aortic intimal fluid.
    Lindstedt L; Lee M; Kovanen PT
    Atherosclerosis; 2001 Mar; 155(1):87-97. PubMed ID: 11223430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of rat mast cell protease 1 activity. Protease inhibition is prevented by heparin proteoglycan.
    Pejler G; Berg L
    Eur J Biochem; 1995 Oct; 233(1):192-9. PubMed ID: 7588746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase.
    Ware JH; Wan XS; Rubin H; Schechter NM; Kennedy AR
    Arch Biochem Biophys; 1997 Aug; 344(1):133-8. PubMed ID: 9244390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic studies on the inhibitions of mast cell chymase by natural serine protease inhibitors: indications for potential biological functions of these inhibitors.
    Fukusen N; Kato Y; Kido H; Katunuma N
    Biochem Med Metab Biol; 1987 Oct; 38(2):165-9. PubMed ID: 3479119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reaction of human skin chymotrypsin-like proteinase chymase with plasma proteinase inhibitors.
    Schechter NM; Sprows JL; Schoenberger OL; Lazarus GS; Cooperman BS; Rubin H
    J Biol Chem; 1989 Dec; 264(35):21308-15. PubMed ID: 2592376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of neutrophil serine proteinases by suramin.
    Cadène M; Duranton J; North A; Si-Tahar M; Chignard M; Bieth JG
    J Biol Chem; 1997 Apr; 272(15):9950-5. PubMed ID: 9092534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tryptase in rat mast cells: properties and inhibition by various inhibitors in comparison with chymase.
    Muramatu M; Itoh T; Takei M; Endo K
    Biol Chem Hoppe Seyler; 1988 Jul; 369(7):617-25. PubMed ID: 3066368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycationic peptides as inhibitors of mast cell serine proteases.
    Lundequist A; Juliano MA; Juliano L; Pejler G
    Biochem Pharmacol; 2003 Apr; 65(7):1171-80. PubMed ID: 12663052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human skin chymotrypsin-like proteinase chymase. Subcellular localization to mast cell granules and interaction with heparin and other glycosaminoglycans.
    Sayama S; Iozzo RV; Lazarus GS; Schechter NM
    J Biol Chem; 1987 May; 262(14):6808-15. PubMed ID: 3553192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of enzymatic activity of human mast cell tryptase and chymase by protease inhibitors.
    He SH; Chen P; Chen HQ
    Acta Pharmacol Sin; 2003 Sep; 24(9):923-9. PubMed ID: 12956943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mast cell chymase is a possible mediator of neurogenic bladder fibrosis.
    Howard PS; Renfrow D; Schechter NM; Kucich U
    Neurourol Urodyn; 2004; 23(4):374-82. PubMed ID: 15227657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degradation of human anaphylatoxin C3a by rat peritoneal mast cells: a role for the secretory granule enzyme chymase and heparin proteoglycan.
    Gervasoni JE; Conrad DH; Hugli TE; Schwartz LB; Ruddy S
    J Immunol; 1986 Jan; 136(1):285-92. PubMed ID: 3510005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential inhibition of mast cell chymases by secretory leukocyte protease inhibitor.
    Pemberton AD; Huntley JF; Miller HR
    Biochim Biophys Acta; 1998 Jan; 1379(1):29-34. PubMed ID: 9468329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of the activity of human chymase during storage and release from mast cells: the contributions of inorganic cations, pH, heparin and histamine.
    McEuen AR; Sharma B; Walls AF
    Biochim Biophys Acta; 1995 Jun; 1267(2-3):115-21. PubMed ID: 7612663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two distinct forms of human mast cell chymase--differences in affinity for heparin and in distribution in skin, heart, and other tissues.
    McEuen AR; Gaça MD; Buckley MG; He S; Gore MG; Walls AF
    Eur J Biochem; 1998 Sep; 256(2):461-70. PubMed ID: 9760188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism by which heparin proteoglycan modulates mast cell chymase activity.
    Pejler G; Sadler JE
    Biochemistry; 1999 Sep; 38(37):12187-95. PubMed ID: 10508424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and structure-activity relationships of a new class of 1-oxacephem-based human chymase inhibitors.
    Aoyama Y; Uenaka M; Konoike T; Iso Y; Nishitani Y; Kanda A; Naya N; Nakajima M
    Bioorg Med Chem Lett; 2000 Nov; 10(21):2397-401. PubMed ID: 11078187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonpeptidic chymase inhibitors: design and structure-activity relationships of pyrimidinone derivatives based on the predicted binding mode of a peptidic inhibitor.
    Akahoshi F
    Curr Pharm Des; 2003; 9(15):1191-9. PubMed ID: 12769746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.